{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 16 October 2007\line \line {\b Strong 
sales growth in the first nine months of 2007 - full-year outlook and Core Earnings per Share target 
reaffirmed\line \line } Release as PDF: \u160?English (http://www.roche.com/mr3q07e.pdf) 
\u160?\u160?\u160?\u160?\u160?German (http://www.roche.com/mr3q07d.pdf) \u160?\u160?\u160?\u160?\u160?French (http://www.roche.com/mr3q07f.pdf) 
\u160?\u160?\u160?\u160?\u160?Spanish (http://www.roche.com/mr3q07sp.pdf)\line \line Presentation 
as PDF (http://www.roche.com/irp3q07e.pdf): (English only)\line \line {\b Roche Group} \par}{\pard\f0\li440\ri0\sl360\fs22 - Group 
sales up 12% in local currencies to 33.9 billion Swiss francs. As anticipated, Tamiflu sales decline 
significantly in third quarter following completion of outstanding pandemic stockpiling orders\par}{\pard\f0\li440\ri0\sl360\fs22 - Full-year 
outlook reaffirmed: Group and Pharmaceuticals Division anticipate double-digit sales increases, and 
both divisions expect above-market growth; target is for Core Earnings per Share to grow faster than 
Group sales\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Pharmaceuticals 
Division} \par}{\pard\f0\li440\ri0\sl360\fs22 - Nine-month pharmaceutical sales up 
14% in local currencies and 13% in Swiss francs, more than twice the global market growth rate\par}{\pard\f0\li440\ri0\sl360\fs22 - Third-quarter 
sales growth, excluding pandemic Tamiflu, reaches 12%, continuing double digit-growth trend of recent 
years \par}{\pard\f0\li440\ri0\sl360\fs22 - All key cancer medicines post double-digit growth\par}{\pard\f0\li440\ri0\sl360\fs22 - Positive 
market response following EU launch of Avastin in advanced lung cancer\par}{\pard\f0\li440\ri0\sl360\fs22 - Mircera 
launched in EU for anemia \u8211? early uptake encouraging\par}{\pard\f0\li440\ri0\sl360\fs22 - Four pivotal 
phase III registration trials with Actemra in rheumatoid arthritis meet primary objectives, regulatory 
filings on track for end of 2007.\par}{\pard\f0\li440\ri0\sl360\fs22 - Phase III studies with Avastin 
in important additional indications initiated (adjuvant non-small cell lung cancer, gastric cancer, 
aggressive non-Hodgkin\u8217?s lymphoma) \par}{\pard\f0\li440\ri0\sl360\fs22 - Phase III studies starting 
with ocrelizumab in rheumatoid arthritis and lupus, and with pertuzumab in metastatic breast cancer\par}{\pard\f0\li440\ri0\sl360\fs22 - Genentech 
completes acquisition of Tanox, Inc.\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Diagnostics 
Division} \par}{\pard\f0\li440\ri0\sl360\fs22 - Sales grow 5% in local currencies 
and 6% in Swiss francs\par}{\pard\f0\li440\ri0\sl360\fs22 - All regions contribute to higher sales, 
with strong growth in Asia-Pacific (18%)\par}{\pard\f0\li440\ri0\sl360\fs22 - Solid growth driven by 
Professional Diagnostics (7%) and Applied Science (10%)\par}{\pard\f0\li440\ri0\sl360\fs22 - Molecular 
Diagnostics\u8217? sales down as expected (-3%) due to a decline in industrial sales\par}{\pard\f0\li440\ri0\sl360\fs22 - Contract 
signed with Japanese Red Cross for blood-screening products\par}{\pard\f0\li440\ri0\sl360\fs22 - NimbleGen 
transaction completed\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 {\pard\f0\li0\ri0\sa360\sl360\fs18 Unless 
otherwise stated, all growth rates are based on local currencies.\par}\line \line Commenting 
on the Group\u8217?s sales performance in the first nine months of 2007, Roche Chairman and CEO Franz B. Humer 
said: \u8216?With its strong 9-month sales growth of 12%, the Roche Group continues to outperform the market. 
Revenue growth in the second half of last year, as we all know, was also driven by a peak in stockpiling 
orders for Tamiflu for use in the event of a pandemic. With those orders now filled, I am all the more 
pleased to report that our Pharmaceuticals Division continued its double-digit growth*, with 12% in 
the third quarter, fuelled by a broad and young portfolio of innovative medicines for cancer, hepatitis 
and osteoporosis. Particularly important for our future growth is the progress being made in our broad 
programme of clinical trials: several important projects are now entering or are ready to enter phase 
III.\u8217?\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 * Without pandemic sales of Tamiflu to governments 
and corporations\par}\line \line \line {\b Roche 
Group} \line {\b Double-digit growth for Roche Group and Pharmaceuticals} \line 
		 20072006% Change% Change
	
		Sales from January to Septemberm CHFmCHFIn CHFIn local currencies
	
		Pharmaceuticals Division27,12423,912+13+14
	
		        Roche 16,79214,921+13+10
	
		        Genentech 7,8506,522+20+24
	
		        Chugai 2,4822,469+1+7
	
		Diagnostics Division6,8236,415+6+5
	
		Roche Group33,94730,327+12+12
	{\pard\f0\li0\ri0\sa360\sl360\fs18 See 
attachment to this release for details on quarterly sales growth.\par}\line \line The 
Roche Group posted sales of 33.9 billion Swiss francs in the first nine months of 2007, an increase 
of 12% in both local currencies and Swiss francs (16% in US dollars) over the same period last year. 
Sales by the Pharmaceuticals Division grew 14% in local currencies (13% in Swiss francs), with Roche 
Pharma advancing 10%, Genentech 24% and Chugai 7%. The Diagnostics Division recorded a sales increase 
of 5% in local currencies (6% in Swiss francs, 10% in US dollars).\line \line {\b Outlook 
for 2007 reaffirmed} \line For full-year 2007 Roche anticipates continued strong growth 
and reaffirms its sales and Core Earnings per Share outlook: Roche expects the Group\u8217?s and the Pharmaceuticals 
Division\u8217?s sales to grow at double-digit rates in local currencies. In both the Pharmaceuticals and 
the Diagnostics Division Roche anticipates continued above-market sales growth. The target is for Core 
Earnings per Share to grow faster than Group sales.\line \line \line {\b Pharmaceuticals 
Division} \line {\b Strong 
above-market performance sustained} \line \line In the first nine months of 
2007 the Pharmaceuticals Division continued its strong double-digit growth, with sales advancing 14% 
in local currencies (13% in Swiss francs; 17% in US dollars). This is more than twice the global market 
average. Sales advanced well ahead of the market in both North America (16% vs 6%) and Europe (12% vs 
6.5%), and in Japan the return to above-market growth (7% vs 3.5%) was maintained. Growth in all regions 
was primarily driven by strong demand for the division\u8217?s oncology products, which now account for half 
of pharmaceutical sales. After peak pandemic stockpiling sales of 1.5 billion Swiss francs in the second 
half of 2006, uptake of Tamiflu by governments and corporations has slowed, as forecast. Excluding pandemic 
sales, the division\u8217?s growth rate in the third quarter was 12%.\line \line {\b Oncology 
- flagship products continue to perform strongly} \line Combined sales of the division\u8217?s 
oncology products increased 21% in the first nine months. This strong growth further reinforces Roche\u8217?s 
position as the world\u8217?s leading provider of cancer medicines.\line \line Sales of 
MabThera/Rituxan (rituximab) for non-Hodgkin\u8217?s lymphoma (NHL) continue to grow strongly, advancing 17% 
globally and 23% in Europe/Rest of World (RoW). Growth is being driven by increasing use of MabThera 
in its new indication as maintenance therapy, adding to sales from its established indications as first 
line treatment of indolent and aggressive NHL. Substantial increases were seen in emerging markets, 
especially in Latin America and in the Asia\u8211?Pacific region.\line \line Global sales 
of Herceptin (trastuzumab), the only targeted therapy with survival benefits in both early and advanced 
HER2-positive breast cancer, continued their strong growth (26%), with particularly large gains in Europe/RoW 
(42%). New data show that, when used preoperatively in combination with chemotherapy, Herceptin can 
eradicate breast tumours in nearly three times as many patients with inflammatory breast cancer (an 
aggressive form of the disease) as chemotherapy alone.\line \line Avastin (bevacizumab) 
sales increased 41% worldwide compared with the same period last year. Sales grew strongly in all regions, 
particularly in Europe/RoW (+58%). Following its European approval in metastatic breast cancer last 
March, Avastin additionally received EU approval in August for the first line treatment of patients 
with advanced non-small cell lung cancer, the most common form of the disease, in combination with platinum-based 
chemotherapy. This indication was approved in the US in 2006. These approvals represent a significant 
advance in the treatment of lung cancer, as this is the first therapy shown to extend survival beyond 
one year. In August Genentech resubmitted its supplemental marketing application to the US Food and 
Drug Administration (FDA) for use of Avastin in combination with paclitaxel as first-line treatment 
of patients with locally recurrent or metastatic breast cancer. Genentech has been notified by the FDA 
that the application will be reviewed by the agency\u8217?s Oncologic Drugs Advisory Committee (ODAC) at a 
meeting in December. The FDA\u8217?s action date for review of the supplemental application is 23 February 
2008. New data from a large international study (First BEAT) presented at the European Cancer Conference 
(ECCO) in September show that, of the 11.5% of patients with initially inoperable metastatic colorectal 
cancer who became eligible for surgery following treatment with Avastin plus standard chemotherapy, 
almost 80% were able to undergo complete surgical removal of their metastatic lesions. This rate of 
curative surgery is higher than that previously seen in trials with other biologic\u8211?chemotherapy combinations.\line \line Xeloda 
(capecitabine) posted double-digit growth (18%), driven by good sales in both the United States (+19%) 
and Europe/RoW (+17%). New follow-up data from the X-ACT trial presented at ECCO show that patients 
with advanced colon cancer whose disease has progressed live longer when taking oral Xeloda compared 
with the current standard treatment, intravenous 5-fluorouracil (5-FU) plus folinic acid. This adds 
to the growing body of evidence that supports replacing 5-FU with Xeloda in colon cancer.\line \line Tarceva 
(erlotinib), the only epidermal growth factor receptor (EGFR) inhibitor with a proven survival benefit 
in advanced lung and pancreatic cancer, continued its strong growth (34%), with Europe/RoW (90%) the 
main driver. In non-small cell lung cancer, interim data from TRUST, a major open-label study of Tarceva 
in more than 12,000 patients from 59 countries, and data from MERIT, the largest prospective genomic 
profiling study ever conducted in this indication, were presented this year at the World Conference 
on Lung Cancer in Seoul (Korea) and at ECCO. Data from both studies reinforce the survival benefits 
that patients experienced in the landmark BR.21 study that earned Tarceva marketing approval in over 
80 countries.\line \line {\b Anemia - Mircera gains European approval, 
rollout starts} \line In July the European authorities approved Mircera (methoxy polyethylene 
glycol-epoetin beta), Roche\u8217?s innovative continuous erythropoietin receptor activator, for the treatment 
of anemia associated with chronic kidney disease (CKD). The prescribing information (label) differentiates 
Mircera from other erythropoiesis-stimulating agents (ESAs) in the EU by allowing twice-monthly administration 
of Mircera for correction of anemia and direct conversion of all CKD patient types to a monthly maintenance 
schedule. The product has just been launched in Austria, Germany, Sweden and the UK, and initial uptake 
is encouraging. The recent approval of Mircera in Switzerland has triggered filings in numerous other 
countries worldwide. Roche is now in discussions with the FDA to finalise the product\u8217?s US label. The 
US court case in the lawsuit brought against Roche by Amgen alleging patent infringement began in early 
September, and a verdict is expected by the end of October.\line \line Combined 
sales of Roche\u8217?s NeoRecormon and Chugai\u8217?s Epogin (epoetin beta) were down 4% in a market that remains 
highly competitive. While the decline in NeoRecormon sales was slight (-2%), sales of Epogin in Japan 
(-10%) continued to be affected by government-mandated price cuts and reimbursement changes.\line \line {\b Transplantation 
- steady growth maintained} \line The immunosuppressant CellCept (mycophenolate mofetil) 
continued to record steady sales growth worldwide (8%), driven by solid sales in both the US and Europe. 
Growth continues to be driven by physicians\u8217? recognition of the long-term protective benefits of CellCept 
compared with other, more toxic therapies.\line \line {\b Virology - significant 
number of Tamiflu pandemic orders filled} \line Worldwide sales of Tamiflu (oseltamivir) 
in the first nine months of 2007 declined 2% compared with the year-earlier period. As anticipated, 
third-quarter 2007 sales were more than 400 million Swiss francs (or 60%) lower than in Q3 2006 , primarily 
because stockpiling orders from governments and corporations as part of pandemic readiness plans have 
largely been completed, and no significant new orders have been received recently. Seasonal sales of 
Tamiflu in Japan have been negatively affected by the mild 2006/2007 flu season and restrictions imposed 
by the authorities on the use of the medicine in adolescents. This has been more than outweighed, however, 
by a substantial increase in pandemic sales to the Japanese government. Recent WHO guidelines have reinforced 
the position of Tamiflu as the treatment of choice for avian influenza (bird flu). \line \line Roche\u8217?s 
hepatitis franchise continues to be led by Pegasys (peginterferon alfa-2a), which delivered steady growth 
of 10% in a flat market. Copegus (ribavirin) sales continued to decline as a result of generic competition 
and were down 10% in the first nine months. Initial market response in Japan to the rollout of combined 
Pegasys plus Copegus for hepatitis C has been positive.\line \line In HIV, Fuzeon 
(enfuvirtide) continues to deliver steady sales growth (10%), particularly in Europe. The recall of 
the HIV medication Viracept (nelfinavir), begun in June following the discovery of a chemical impurity 
in some production batches, has been implemented in all markets where Roche supplies the product. In 
September the Committee for Medicinal Products for Human Use (CHMP) recommended reinstating the suspended 
marketing authorisation for Viracept in the European Union. The Committee stated that it is satisfied 
with the actions taken by Roche. The final decision on lifting the suspension rests with the European 
Commission.\line \line {\b Autoimmune diseases - increasing adoption of 
MabThera/Rituxan in rheumatoid arthritis} \line Adoption by physicians of MabThera/Rituxan 
(rituximab) for rheumatoid arthritis (RA) continues to increase. New data presented at the annual meeting 
of the European League Against Rheumatism (EULAR) in June demonstrate that the product\u8217?s effectiveness 
in relieving the distressing symptoms of RA is sustained or further improved with subsequent courses 
of treatment, as is the number of patients achieving remission. The data also show that the safety profile 
of MabThera/Rituxan remained unchanged in patients who had received as many as seven courses of treatment 
at 6- to 12-month intervals. A recent study in patients whose RA had responded inadequately to one or 
more tumour necrosis factor (TNF) inhibitors found that treatment with MabThera controlled disease activity 
more effectively than switching to another TNF inhibitor.\line \line MabThera/Rituxan 
is currently approved for use in patients with active RA who have an inadequate response to or are unable 
to tolerate TNF inhibitor therapy. It was recently recommended by the National Institute for Clinical 
Excellence (NICE) in England and Wales, making it the first and only therapy recommended by the Institute 
for patients with an inadequate response to one or more TNF inhibitor therapies.\line \line {\b Metabolic 
Diseases - new data support Bonviva/Boniva} \line In a highly competitive market, nine-month 
sales of Bonviva/Boniva (ibandronic acid) for the treatment of postmenopausal osteoporosis almost doubled 
to 604 million Swiss francs compared with the previous-year period. New data strengthening the product\u8217?s 
efficacy profile were presented at the annual meeting of the American Society of Bone Mineral Research 
in September.\line \line Sales of the prescription weight-loss medication Xenical 
(orlistat 120 mg) declined 8% worldwide and 21% in the United States, where Roche\u8217?s partner GlaxoSmithKline 
is successfully launching non-prescription orlistat 60 mg under the brand name alli. As licensor, Roche 
will receive royalties on sales of alli.\line \line In August Genentech announced 
that it had completed the acquisition of Tanox, Inc. The acquisition gives Genentech improved profitability 
on Xolair (omalizumab), the asthma medication jointly developed and commercialised by Genentech, Tanox 
and Novartis. Through the acquisition, Genentech eliminates the royalty on Xolair sales which it previously 
paid to Tanox and obtains Novartis\u8217? profit share and royalty payments to Tanox.\line \line {\b Development 
- major additions to pipeline and growth prospects}  \line As of 30 September 2007 the 
Pharmaceuticals Division\u8217?s R&D pipeline (phase I to III/registration) included 58 new molecular 
entities (NMEs) and 56 additional indications (AIs). During the third quarter of 2007 the following 
major pipeline changes occurred: two projects entered phase II; one phase II project was discontinued; 
five projects entered phase III, and two projects received regulatory approval; no phase III projects 
were discontinued.\line \line The development programme for Avastin continues to 
make steady progress. Additional important phase III trials have started, studying use of the product 
in early-stage non-small cell lung cancer and metastatic gastric (stomach) cancer, as well as combined 
MabThera and Avastin in aggressive non-Hodgkin\u8217?s lymphoma. Phase III studies with pertuzumab in metastatic 
breast cancer are expected to start before the end of 2007.\line \line Actemra (tocilizumab), 
an innovative IL-6 receptor inhibitor in development as a novel treatment for rheumatoid arthritis (RA), 
has passed another milestone with the announcement in July of phase III study results that for the first 
time showed superiority of monotherapy with a biologic medicine over the standard effective dose regimen 
of methotrexate, a drug commonly use to treat RA. This is the fourth international phase III trial to 
meet its primary objective. Preparations for marketing applications in the United States and the European 
Union based on the data from all four trials are on schedule. Roche expects to submit these by the end 
of 2007. A fifth international study is progressing on track, with results expected towards the end 
of 2008.\line \line Ocrelizumab, a humanised anti-CD20 monoclonal antibody, is now 
in phase III development for RA, with three trials by Roche and Genentech currently ongoing. Ocrelizumab 
is also being investigated as a potential treatment for other autoimmune diseases, including systemic 
lupus erythematosus and multiple sclerosis. Phase III studies in lupus are expected to start in November. 
Phase II studies with ocrelizumab in patients with relapsing-remitting multiple sclerosis are currently 
being prepared.\line \line Based on preliminary results released in June from an 
ongoing phase III trial of CellCept in lupus nephritis conducted by Aspreva, Roche and Aspreva have 
decided not to proceed at this time with a regulatory filing for the product as induction therapy for 
this autoimmune condition. \line \line {\b Progress in mid-stage development 
pipeline} \line In addition to its ongoing programme to investigate combined Pegasys and 
Copegus in additional hepatitis indications, Roche is developing a number of potential new treatments 
for hepatitis C virus (HCV) infection. R1626, currently in phase II clinical testing, is a polymerase 
inhibitor that has shown robust antiviral effects; it is being studied in combination with Pegasys and 
Copegus. Roche also has promising anti-HCV compounds in phase I development, including the polymerase 
inhibitor R7128 (collaboration with Pharmasset) and the protease inhibitor R7227 (collaboration with 
InterMune).\line \line In the autoimmune area Roche has decided to terminate development 
of R1503 (p38 kinase inhibitor, for RA) as it did not reach the predefined efficacy threshold. Clinical 
testing of other promising oral drug candidates for autoimmune diseases, including R3421 (PNP inhibitor, 
in phase II with BioCryst) and R3477 (S1P1 receptor agonist, in phase I with Actelion), is progressing 
on track.\line \line In the diabetes and metabolic diseases area Roche has moved 
R1579 (DPP-IV inhibitor) into phase II clinical trials. First data from phase IIb testing of R1583 (GLP-1, 
sustained-release formulation) are expected before year-end. Both molecules are being developed to treat 
type 2 diabetes. Following encouraging data from phase II studies with the CETP inhibitor R1658 (dyslipidemia, 
collaboration with Japan Tobacco) and positive discussions with the health authorities, Roche is now 
close to a phase III decision on this promising molecule.\line \line \line {\b Diagnostics 
Division } \line {\b Professional Diagnostics and Applied 
Science 
drive sales growth} \line \line Roche Diagnostics posted sales of 6.8 billion 
Swiss francs in the first nine months of 2007, an increase of 5% in local currencies (6% in Swiss francs, 
10% in US dollars) over the year-earlier period. Professional Diagnostics reported solid single-digit 
growth, and Applied Diagnostics double-digit growth. The Diabetes Care business increased its sales 
4%. Molecular Diagnostics\u8217? nine-month sales declined 3% overall but grew 3% excluding industrial reagents. 
All regions contributed to growth, with divisional sales showing single-digit gains in the EMEA region 
(Europe, Middle East, Africa), North America and Japan and double-digit growth in Asia\u8211?Pacific and Latin 
America. The acquisition of US-based NimbleGen Systems, Inc., a leading supplier of high-density microarrays, 
was completed in August.\line \line {\b Professional Diagnostics - above-market 
immunoassay sales continue} \line Roche Professional Diagnostics (formerly Centralized 
Diagnostics and Near Patient Testing) reported an overall sales increase of 7%. The increase was led 
by immunoassay sales, which continued to grow at a rate of 12%, or twice as fast as the market. Top-selling 
assays included tests for the cardiac markers troponin T and NT-proBNP and for the thyroid marker TSH 
(thyroid-stimulating hormone). In July a vitamin D test was added to the bone marker menu for diagnosing 
osteoporosis. Clinical chemistry sales continued to grow in line with the market.\line \line Strong 
demand continues for the cobas 6000 analyser series, launched last year for medium-volume laboratories. 
The cobas e 411 immunochemistry analyser, the first in the new cobas 4000 series for small-volume laboratories, 
is already on the market, and a clinical chemistry instrument for the series will follow in the fourth 
quarter of this year.\line \line Products for decentralised testing were again significant 
growth drivers. The underlying growth of the coagulation self-monitoring business remains strong thanks 
to the CoaguChek platform. Sales of point-of-care cardiac assays have continued to accelerate, particularly 
in Europe, following the launch of the portable cobas h 232 cardiac testing system in February.\line \line Sales 
of hospital glucose testing products continued their strong upward trend, led by the US market. In ambulatory 
care, the cobas h 152 was launched in September as a successor to the highly successful Accutrend line. 
This easy-to-use device is the first handheld meter capable of measuring glucose, cholesterol, triglycerides 
and lactate in blood.\line \line {\b Diabetes Care - strong uptake of 
Accu-Chek Spirit insulin pump} \line Roche Diabetes Care\u8217?s nine-month sales grew 4% in 
the face of increasing reimbursement pressures in the United Kingdom and Germany, and slower market 
growth in the United States and other key markets. These factors affected both volume and price growth. 
The Accu-Chek Aviva, Accu-Chek Performa and Accu-Chek Compact blood glucose monitors were the main growth 
drivers. The Accu-Chek Spirit insulin pump delivered strong double-digit growth. The most recent upgrade 
of the Accu-Chek Compact Plus, an integrated monitoring system combining test strips and lancing capabilities 
in a single device, premiered in September at this year\u8217?s annual meeting of the European Association 
for the Study of Diabetes and will be rolled out to markets starting in the fourth quarter of this year. 
Roche remains the clear leader in the growing integrated glucose monitor segment. \line \line North 
American sales advanced at a single-digit rate for the first nine months. The Accu-Chek Spirit insulin 
pump has been well received and continues to attract customers in the United States, where it was launched 
in late 2006. The global rollout of the Accu-Chek Performa monitor continued with launches in Argentina 
and France. The new Accu-Chek Compact Plus and the Accu-Chek Performa are expected to contribute to 
increased fourth-quarter sales growth.\line \line {\b Molecular Diagnostics 
- blood screening contract signed with Japanese Red Cross} \line Roche Molecular Diagnostics 
maintained its leading market share, with nine-month sales down 3% from the same period in 2006. Excluding 
industrial reagents, sales were up 3%. Virology, one of the business area\u8217?s largest segments, grew 3%, 
driven by placements of the automated Cobas AmpliPrep/Cobas TaqMan platform in Europe, Asia\u8211?Pacific 
and the United States.\line \line In the blood screening segment, the US Food and 
Drug Administration (FDA) approved the cobas TaqScreen West Nile Virus Test, which is also under regulatory 
review in Canada. Commercialisation of the test in the United States began in September. The Japanese 
Red Cross has awarded Roche a contract to supply its fully integrated, next-generation cobas s 401 instrument 
and multiplexing reagents to screen the entire Japanese Red Cross blood supply (five million blood donations 
annually) for HIV and hepatitis B and C viruses (HBV, HCV). The contract will be effective from 2008. 
In addition, FDA reviews are under way of a multiplex blood screening test for HIV, HCV and HBV and 
of HBV and HCV tests for the virology segment.\line \line {\b Applied 
Science - life science products drive growth} \line Roche Applied Science posted a 10% 
increase in nine-month sales. The LightCycler 480 and Genome Sequencer 20 systems and research reagents 
were again the main growth drivers.\line \line The acquisition in August of NimbleGen 
Systems, Inc., a pioneer in DNA microarrays, has brought Roche a step closer to its strategic goal of 
providing complete workflow solutions for the genomics and post-genomics life science markets. This 
followed the acquisition of 454 Life Sciences in May, a deal that reinforces Roche\u8217?s position as a major 
player in the genome sequencing market.\line \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world\u8217?s 
biggest biotech company and an innovator of products and services for the early detection, prevention, 
diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and 
transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune 
diseases, inflammation, metabolic disorders and diseases of the central nervous system. In 2006 sales 
by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted 
sales of 8.7 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous 
partners, including majority ownership interests in Genentech and Chugai, and invests approximately 
7 billion Swiss francs a year in R&D. Worldwide, the Group employs about 75,000 people. Additional 
information is available on the Internet at www.roche.com (http://www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\line \line Annex (http://www.roche.com/mr3q07ane.pdf)\line \line \line {\b Additional 
information} \line - Roche Pharma pipeline (http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm)\line \line \line {\b Next 
event} \line - Full-year results 2007: 30 January 2008 (tentative date)\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 Disclaimer: 
Cautionary statement regarding forward-looking statements\line This document contains certain 
forward-looking statements. These forward-looking statements may be identified by words such as \u8216?believes\u8217?, 
\u8216?expects\u8217?, \u8216?anticipates\u8217?, \u8216?projects\u8217?, \u8216?intends\u8217?, \u8216?should\u8217?, \u8216?seeks\u8217?, \u8216?estimates\u8217?, \u8216?future\u8217? or similar 
expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors 
may cause actual results to differ materially in the future from those reflected in forward-looking 
statements contained in this document, among others: (1) pricing and product initiatives of competitors; 
(2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining 
regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and 
general financial market conditions; (5) uncertainties in the discovery, development or marketing of 
new products or new uses of existing products, including without limitation negative results of clinical 
trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased 
government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate 
protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; 
and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not 
a profit forecast and should not be interpreted to mean that Roche\u8217?s earnings or earnings per share 
for any current or future period will necessarily match or exceed the historical published earnings 
or earnings per share of Roche.\par}\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}